• 中药标准品生产商,产品定制服务
  • 淫羊藿苷


    产品编号 CFN99554
    CAS编号 489-32-7
    分子式 = 分子量 C33H40O15 = 676.65
    产品纯度 >=98%
    物理属性 Yellow powder
    化合物类型 Flavonoids
    植物来源 The herbs of Epimedium grandiflorum
    产品名称 产品编号 CAS编号 包装 QQ客服
    淫羊藿苷 CFN99554 489-32-7 10mg QQ客服:3257982914
    淫羊藿苷 CFN99554 489-32-7 20mg QQ客服:3257982914
    淫羊藿苷 CFN99554 489-32-7 50mg QQ客服:3257982914
    淫羊藿苷 CFN99554 489-32-7 100mg QQ客服:3257982914
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
  • Melbourne University (Australia)
  • Max Rubner-Institut (MRI) (Germany)
  • University of Fribourg (Switzerland)
  • University of Maryland School of Medicine (USA)
  • Universidade Federal de Goias (UFG) (Brazil)
  • Leibniz-Institut für Pflanzenbiochemie (IPB) (Germany)
  • CSIRO - Agriculture Flagship (Australia)
  • University of Madras (India)
  • The Institute of Cancer Research (United Kingdom)
  • Medizinische Universit?t Wien (Austria)
  • Universidade Federal de Santa Catarina (Brazil)
  • University of Indonesia (Indonesia)
  • University of Wollongong (Australia)
  • Korea Intitute of Science and Technology (KIST) (Korea)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Int J Mol Med.2016, 37(2):501-8
  • Int. Conference on Med. Sci. and Bio.2017, 17973
  • Int J Mol Sci.2017, 18(5)
  • J Ethnopharmacol.2017, 206:327-336
  • Plant Cell Tiss Org2017, 479-486
  • Evid Based Complement Alternat Med.2018, 2018:1073509
  • RSC Adv.2018, 32621-32636
  • Biosci Rep.2018, 38(4)
  • Curr Eye Res.2018, 43(1):27-34
  • Biofactors.2018, 44(2):168-179
  • Sci Rep.2018, 8(1):12970
  • Cancer Manag Res.2019, 11:483-500
  • J Ethnopharmacol.2019, 236:31-41
  • Molecules.2019, 24(1):E159
  • Molecules.2019, 25(1):E103
  • Pak J Pharm Sci.2019, 32(6)
  • Pak J Pharm Sci.2019, 32(6):2879-2885
  • Food and Fermentation Industries2019, 45(7):45-51
  • J Asian Nat Prod Res.2019, 5:1-17
  • Environ Toxicol Pharmacol.2019, 66:109-115
  • Genes Genomics.2020, 10.1007
  • J Pharmaceut Biomed2020, 178:112894
  • Biochem Biophys Res Commun.2020, 522(1):40-46
  • ...
  • 生物活性
    Description: Icariin inhibits PDE5 and PDE4 activities with IC50s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator. Icariin has been reported to have anti-hypoxic, phytoestrogenic, anti-osteoporotic, anti-inflammatory, neuroprotective, and anti-depressant-like activities. Icariin is effective in the attenuation of AHR and chronic airway inflammatory changes in OVA-induced murine asthma model, and this effect is associated with regulation of Th17/Treg responses. Icariin inhibited NF-κB signaling activation and the NLRP3-inflammasome/caspase-1/IL-1β axis.
    Targets: gp120/CD4 | IL Receptor | NF-kB | TNF-α | NOS | p38MAPK | TGF-β/Smad | PPAR | IkB | IKK | PDE-5 | PDE-4
    In vitro:
    J Cell Biochem. 2015 Apr;116(4):580-8.
    Icariin inhibits foam cell formation by down-regulating the expression of CD36 and up-regulating the expression of SR-BI.[Pubmed: 25389062 ]
    Icariin is an important pharmacologically active flavonol diglycoside that can inhibit inflammation in lipopolysaccharide (LPS)-stimulated macrophages. However, little is known about the molecular mechanisms underlying the inhibitory effect of Icariin in the formation of foam cells.
    In this study, macrophages were cultured with LPS and oxidized low-density lipoprotein (oxLDL) in the presence or absence of Icariin. RT-PCR and western blot were used to detect the levels of mRNA and protein expression of CD36, scavenger receptor class B type I (SR-BI) and the phosphorylation of p38MAPK. It was demonstrated that 4 μM or 20 μM Icariin treatment significantly inhibited the cholesterol ester (CE)/total cholesterol (TC) and oxLDL-mediated foam cell formation (P < 0.05). The binding of oxLDL to LPS-activated macrophages was also significantly hindered by Icariin (P < 0.05). Furthermore, Icariin down-regulated the expression of CD36 in LPS-activated macrophages in a dose-dependent manner and CD36 over-expression restored the inhibitory effect of Icariin on foam cell formation. The phosphorylation of p38MAPK was reduced by Icariin, indicating that Icariin reduced the expression of CD36 through the p38MAPK pathway. In addition, Icariin up-regulated SR-BI protein expression in a dose-dependent manner, and SR-BI gene silencing restored the inhibitory effect of Icariin on foam cell formation. These data demonstrate that Icariin inhibited foam cell formation by down-regulating the expression of CD36 and up-regulating the expression of SR-BI.
    Therefore, our findings provide a new explanation as to why Icariin could inhibit atherosclerosis.
    In vivo:
    Immunobiology. 2015 Jun;220(6):789-97.
    Regulation of Th17/Treg function contributes to the attenuation of chronic airway inflammation by icariin in ovalbumin-induced murine asthma model.[Pubmed: 25613226]
    Icariin which is a flavonoid glucoside isolated from Epimedium brevicornu Maxim, has been reported to have anti-osteoporotic, anti-inflammatory and anti-depressant-like activities.
    In this study, we observed the effect of icariin on airway inflammation of ovalbumin (OVA)-induced murine asthma model and the associated regulatory mode on T-helper (Th)17 and regulatory T (Treg) cell function. Our data revealed that chronic OVA inhalation induced a dramatic increase in airway resistance (RL) and decrease in the lung dynamic compliance (Cdyn), and icariin and DEX treatment caused significant attenuation of such airway hyperresponsiveness (AHR). BALF cell counts demonstrated that icariin and DEX led to a prominent reduction in total leukocyte as well as lymphocyte, eosinophil, neutrophil, basophil and monocyte counts. Histological analysis results indicated that icariin and DEX alleviated the inflammatory cells infiltrating into the peribronchial tissues and goblet cells hyperplasia and mucus hyper-production. Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORγt+ T cells and elevation of CD4+Foxp3+ T cells in BALF. Furthermore, icariin or DEX caused a significant reduction in IL-6, IL-17 and TGF-β level in BALF. Unfortunately, icariin had no effect on IL-10 level in BALF. Western blot assay found that icariin or DEX suppressed RORγt and promoted Foxp3 expression in the lung tissue. qPCR analysis revealed that icariin and DEX resulted in a notable decrease in RORγt and increase in Foxp3 mRNA expression in isolated spleen CD4+ T cell.
    In conclusion, our results suggested that icariin was effective in the attenuation of AHR and chronic airway inflammatory changes in OVA-induced murine asthma model, and this effect was associated with regulation of Th17/Treg responses, which indicated that icariin may be used as a potential therapeutic method to treat asthma with Th17/Treg imbalance phenotype.
    Int Immunopharmacol. 2016 Jan;30:157-162.
    Icariin attenuates cerebral ischemia-reperfusion injury through inhibition of inflammatory response mediated by NF-κB, PPARα and PPARγ in rats.[Pubmed: 26679678 ]
    Icariin (ICA), an active flavonoid extracted from Chinese medicinal herb Epimedii, has been reported to exhibit many pharmacological effects including alleviating brain injury. However, little is known about the protection of ICA on ischemic stroke. Hence, this study was designed to investigate the neuroprotective effect of ICA and explore its underlying mechanisms on ischemic stroke induced by cerebral ischemia-reperfusion (I/R) injury in rats.
    The animals were pretreated with ICA at doses of 10, 30mg/kg twice per day for 3 consecutive days followed by cerebral I/R injury induced by middle cerebral artery occlusion (MCAO) for 2h and reperfusion for 24h. Neurological function and infarct volume were observed at 24h after reperfusion, the protein expression levels of interleukin-1β (IL-1β), transforming growth factor-β1 (TGF-β1), PPARα and PPARγ, inhibitory κB-α (IκB-α) degradation and nuclear factor κB (NF-κB) p65 phosphorylation were detected by Western blot, respectively. It was found that pretreatment with ICA could decrease neurological deficit score, diminish the infarct volume, and reduce the protein levels of IL-1β and TGF-β1. Moreover, ICA suppressed IκB-α degradation and NF-κB activation induced by I/R. Furthermore, the present study also showed that ICA up-regulated PPARα and PPARγ protein levels.
    These findings suggest that ICA has neuroprotective effect on ischemic stroke in rats through inhibition of inflammatory responses mediated by NF-κB and PPARα and PPARγ.
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.4779 mL 7.3893 mL 14.7787 mL 29.5574 mL 36.9467 mL
    5 mM 0.2956 mL 1.4779 mL 2.9557 mL 5.9115 mL 7.3893 mL
    10 mM 0.1478 mL 0.7389 mL 1.4779 mL 2.9557 mL 3.6947 mL
    50 mM 0.0296 mL 0.1478 mL 0.2956 mL 0.5911 mL 0.7389 mL
    100 mM 0.0148 mL 0.0739 mL 0.1478 mL 0.2956 mL 0.3695 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    朝藿定B1; Epimedin B1 CFN95017 133137-58-3 C38H48O19 = 808.8 5mg QQ客服:3257982914
    茂藿苷B; Maohuoside B CFN91887 849834-04-4 C39H50O20 = 838.80 5mg QQ客服:1413575084
    朝藿定C; Epimedin C CFN99941 110642-44-9 C39H50O19 = 822.80 20mg QQ客服:215959384
    朝藿定A1; Epimedin A1 CFN99145 140147-77-9 C39H50O20 = 838.8 20mg QQ客服:2932563308
    朝藿定A; Epimedin A CFN99939 110623-72-8 C39H50O20 = 838.80 20mg QQ客服:215959384
    朝藿苷E; Caohuoside E CFN95016 174286-23-8 C43H54O22 = 922.9 5mg QQ客服:2932563308
    朝藿定K; Epimedin K CFN95019 174286-13-6 C45H56O23 = 964.9 5mg QQ客服:3257982914
    淫羊藿次苷; Icariside I CFN92550 56725-99-6 C27H30O11 = 530.5 20mg QQ客服:2159513211
    茂藿苷A; Maohuoside A CFN98523 128988-55-6 C27H32O12 = 548.5 5mg QQ客服:1148253675
    大花淫羊藿苷F; Ikarisoside F CFN90138 113558-14-8 C31H36O14 = 632.62 5mg QQ客服:1413575084





    在线QQ: 1413575084


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产